InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
12.11.2025 15:00:00 CET | Business Wire | Press Release
InterSystems, a creative data technology provider powering more than 1 billion health records worldwide, today announced the launch of InterSystems HealthShare AI Assistant, a new generative AI capability designed to assist clinicians, case managers, and administrators in accessing and understanding patient information faster and more intuitively.
Built on the trusted foundation of InterSystems HealthShare Unified Care Record (UCR), HealthShare AI Assistant introduces a conversational interface that enables users to securely query, summarize, and navigate complex longitudinal health records using natural language prompts. The AI Assistant queries records from thousands of diverse clinical data sources and leverages Generative AI to surface relevant insights and present information using industry-standard displays—empowering users with faster, more intuitive access to comprehensive patient data and key insights.
Some key capabilities of HealthShare AI Assistant include:
- Conversational Chat Interface - Empowers users to ask clinical questions or request patient summaries in plain language, delivering concise, context-aware insights instantly.
- Pre-Built and Custom Prompts - Provides clinically curated starter prompts and enables organizations to build tailored, role-based configurations.
- Source Traceability - Connects every AI-generated response to its verified record source, promoting transparency and clinical trust.
- Seamless Integration - Operates within the HealthShare Clinical Viewer and Navigation Application keeping the assistant embedded in the user's natural workflow.
- Comprehensive Governance - Implements configurable data profiles, role-based access controls, and full audit tracking to support safe, responsible AI use.
“AI in healthcare must be grounded in trust, interoperability, and reliable data,” said Don Woodlock, head of global healthcare solutions at InterSystems. “With HealthShare AI Assistant, we’re giving healthcare professionals a faster and safer way to access the information they need, right from within their existing workflows. It’s about reducing cognitive burden, improving efficiency, and letting clinicians focus on caring for patients.”
HealthShare AI Assistant pilot programs have demonstrated meaningful gains in efficiency and user satisfaction. A usability study run with Healthix, one of the largest public health information exchanges in the United States, showed that the AI Assistant quantitatively improved clinician workflow, reduced time spent reviewing records, and surfaced useful and actionable insights.
“Collecting information from 9,000+ facilities for over 21 million patients comes with an abundance of data,” said Todd Rogow, CEO at Healthix. “With HealthShare AI Assistant, our clinician users now have a tool to get an instant, clinically validated summary drawn from years of records, delivering a holistic view of a patient's medical history at time of care.”
HealthShare AI Assistant is part of the broader InterSystems HealthShare suite, which powers data interoperability and connected care across more than 80 countries. The new AI capability is available immediately to HealthShare users in supported regions.
For more information, visit www.InterSystems.com/HealthShare.
About InterSystems
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain customers in more than 80 countries. Our data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its 24×7 support for customers and partners around the world. Privately held and headquartered in Boston, Massachusetts, InterSystems has 38 offices in 28 countries worldwide. For more information, please visit InterSystems.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112864064/en/
Contacts
InterSystems PR Contact:
Zach Keating
pr@intersystems.com
617.551.5158
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom